RECRUITING

Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A study conducting to see how well a treatment called Botulinum Toxin Type A works for reducing facial wrinkles. The study will help us understand if this treatment is safe and effective for making wrinkles on the face less noticeable.

Official Title

Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation

Quick Facts

Study Start:2024-05-22

Study Completion:2027-01-05

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06385171

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:20 Years to 65 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Not specified

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Individuals of both genders. * Must be in good physical health. * Age between 20 and 65 years. * Presence of both static (unchanging) and moderate dynamic (movement-induced) wrinkles on the forehead or glabellar region. * Must possess the willingness and ability to understand and provide informed consent, as well as effectively communicate with study personnel.	* Pregnant or breastfeeding female. * Age below 20 or above 65 years. * History of neuromuscular disorders, such as myasthenia gravis. * History of facial surgery or presence of scars in the treatment area that could potentially interfere with or confound the results of the study. * Recent treatment history within the past 6 months in the forehead or glabellar region, including: * Ablative laser procedures. * Radiofrequency device treatments. * Ultrasound device treatments. * Medium to deep chemical peels. * Temporary soft tissue augmentation. * Semi-permanent soft tissue augmentation within the past 2 years. * Permanent soft tissue augmentation. * Planned cosmetic procedures within the next 6 months in the same region. * Intended use of tretinoin or retinoic acid within the next 6 months. * Presence of active infection in the treated area, excluding mild acne. * Allergy to cow's milk protein or albumin. * Use of aminoglycoside medications. * Current use of anticoagulation therapy. * History of bleeding disorders. * Diagnosis of mental illness. * Inability to comprehend the study protocol or provide informed consent.

Inclusion Criteria

Exclusion Criteria

* Individuals of both genders.
* Must be in good physical health.
* Age between 20 and 65 years.
* Presence of both static (unchanging) and moderate dynamic (movement-induced) wrinkles on the forehead or glabellar region.
* Must possess the willingness and ability to understand and provide informed consent, as well as effectively communicate with study personnel.

* Pregnant or breastfeeding female.
* Age below 20 or above 65 years.
* History of neuromuscular disorders, such as myasthenia gravis.
* History of facial surgery or presence of scars in the treatment area that could potentially interfere with or confound the results of the study.
* Recent treatment history within the past 6 months in the forehead or glabellar region, including:
* Ablative laser procedures.
* Radiofrequency device treatments.
* Ultrasound device treatments.
* Medium to deep chemical peels.
* Temporary soft tissue augmentation.
* Semi-permanent soft tissue augmentation within the past 2 years.
* Permanent soft tissue augmentation.
* Planned cosmetic procedures within the next 6 months in the same region.
* Intended use of tretinoin or retinoic acid within the next 6 months.
* Presence of active infection in the treated area, excluding mild acne.
* Allergy to cow's milk protein or albumin.
* Use of aminoglycoside medications.
* Current use of anticoagulation therapy.
* History of bleeding disorders.
* Diagnosis of mental illness.
* Inability to comprehend the study protocol or provide informed consent.

Contacts and Locations

Study Contact

Otis Scroggins, BS, CNA

CONTACT

8063707428

fakefaceaesthetics@gmail.com

Principal Investigator

Otis Scroggins, BS, CNA

PRINCIPAL_INVESTIGATOR

Global Aesthetics LLC

Study Locations (Sites)

Global Aesthetics LLC

Cisco, Texas, 76437

United States

Global Aesthetics LLC

Lubbock, Texas, 79413

United States

Collaborators and Investigators

Sponsor: Global Aesthetics LLC

Otis Scroggins, BS, CNA, PRINCIPAL_INVESTIGATOR, Global Aesthetics LLC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-22

Study Completion Date2027-01-05

Study Record Updates

Study Start Date2024-05-22

Study Completion Date2027-01-05

Terms related to this study

Keywords Provided by Researchers

Facial Wrinkles

Additional Relevant MeSH Terms

Wrinkle